argenx SE (MEX:ARGXN) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


MEX:ARGXN argenx SE MEX:ARGXN
63 GF Score
Price MXN13,000.67
GF Value MXN20,951.12
! 5 Warning Signs
View Full Analysis

What is argenx SE Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

argenx SE's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

MEX:ARGXN vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, argenx SE's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

argenx SE Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, argenx SE's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where argenx SE's Margin of Safety % (DCF Earnings Based) falls into.


MEX:ARGXN
63GF Score
argenx SE MEX:ARGXN
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is argenx SE (MEX:ARGXN) Overvalued in 2026?

Based on GuruFocus' analysis, argenx SE stock appears to be undervalued. The current stock price of MXN13,000.67 is trading 37.9% below its estimated GF Value™ of MXN20,951.12.

Key valuation signals for MEX:ARGXN:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: MXN20,951.12 vs. price of MXN13,000.67 (37.9% below fair value)
  • GF Score™: 63/100 with 5 warning signs

No single metric tells the full story. See the MEX:ARGXN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

argenx SE Business Description

Address Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
63GF Score

Get the complete analysis for MEX:ARGXN

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN13,000.67
Price
MXN20,951.12
GF Value